WallStreetZenWallStreetZen

NASDAQ: REPL
Replimune Group Inc Stock Forecast, Predictions & Price Target

Analyst price target for REPL

Based on 3 analysts offering 12 month price targets for Replimune Group Inc.
Min Forecast
$13.00+44.93%
Avg Forecast
$37.67+319.92%
Max Forecast
$52.00+479.71%

Should I buy or sell REPL stock?

Based on 3 analysts offering ratings for Replimune Group Inc.
Strong Buy
Strong Buy
1 analysts 33.33%
Buy
2 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their REPL stock forecasts and price targets.

REPL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-12-06
lockedlocked$00.00+00.00%2023-11-13
lockedlocked$00.00+00.00%2023-11-08

1 of 1

Forecast return on equity

Is REPL forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.11%

Forecast return on assets

Is REPL forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

REPL revenue forecast

What is REPL's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$300.0k
Avg 2 year Forecast
$34.6M
Avg 3 year Forecast
$125.1M

REPL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
REPL$8.97$37.67+319.92%Strong Buy
URGN$17.77$43.00+141.98%Buy
APLT$7.07$9.50+34.37%Strong Buy
ATXS$14.98$20.00+33.51%Buy
MRNS$9.92$25.25+154.54%Strong Buy

Replimune Group Stock Forecast FAQ

Is Replimune Group Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: REPL) stock is to Strong Buy REPL stock.

Out of 3 analysts, 1 (33.33%) are recommending REPL as a Strong Buy, 2 (66.67%) are recommending REPL as a Buy, 0 (0%) are recommending REPL as a Hold, 0 (0%) are recommending REPL as a Sell, and 0 (0%) are recommending REPL as a Strong Sell.

If you're new to stock investing, here's how to buy Replimune Group stock.

What is REPL's revenue growth forecast for 2025-2027?

(NASDAQ: REPL) Replimune Group's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 45.89%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.82%.

Replimune Group's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast REPL's revenue for 2025 to be $18,416,336, with the lowest REPL revenue forecast at $18,416,336, and the highest REPL revenue forecast at $18,416,336. On average, 4 Wall Street analysts forecast REPL's revenue for 2026 to be $2,126,595,683, with the lowest REPL revenue forecast at $993,868,255, and the highest REPL revenue forecast at $3,703,525,129.

In 2027, REPL is forecast to generate $7,679,980,355 in revenue, with the lowest revenue forecast at $5,567,872,190 and the highest revenue forecast at $10,639,117,192.

What is REPL's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: REPL) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is REPL's Price Target?

According to 3 Wall Street analysts that have issued a 1 year REPL price target, the average REPL price target is $37.67, with the highest REPL stock price forecast at $52.00 and the lowest REPL stock price forecast at $13.00.

On average, Wall Street analysts predict that Replimune Group's share price could reach $37.67 by Dec 6, 2024. The average Replimune Group stock price prediction forecasts a potential upside of 319.92% from the current REPL share price of $8.97.

What is REPL's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: REPL) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.